Current Report · Items 2.02, 9.01 · 8-K

NeuroOne Medical Technologies Corporation

NMTCNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed May 12, 2026Accepted May 12, 2026, 8:10 AM EDTCIK 1500198Accession 0001213900-26-054744

Company context

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Current securities

NMTCNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On May 12, 2026, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 of this Current Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) ea029009401ex99-1.htm

EX-99.1 2 ea029009401ex99-1.htm PRESS RELEASE, DATED MAY 12, 2026 Exhibit 99.1 NeuroOne Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update Product Revenue of $2.4 Million up 72% Year Over Year Successfully Completed 16 Trigeminal Neuralgia Cases to Date, With All Patients Reportedly Pain Free* Management to Host Conference Call Today at 8:30 a.m. Eastern Time EDEN PRAIRIE, Minn., May 12, 2026 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and a business update for the second quarter of fiscal year 2026 ended March 31, 2026. Company Highlights Product revenue was $2.4M for the quarter, a 72% increase versus product revenue of $1.4 million in the second quarter of fiscal 2025. To date, the Company successfully completed 16 cases using the OneRF® Trigeminal Nerve Ablation System for the treatment of facial pain known as trigeminal neuralgia, with all patients reportedly pain free after the procedure.* A new high-net-worth investor acquired a…

Open exhibit ↗

Get the free weekly BCS email.